As a preclinical CRO with 15+ years of experience supporting complex R&D programs for a wide array of startup, biotech and large pharmaceutical companies, Powered Research delivers tightly controlled, end-to-end studies designed for rapid decisions based on quality data generation.
Our expert Leadership Team share decades of drug development experience.
Beth Hollister is your dedicated contact for preclinical oncology studies (view Beth's CV). Use the contact form below to reach out to her.
We offer a full suite of services for evaluating potential cancer therapeutics, from experimental design and in vivo tumor modeling to extensive endpoint analyses.
Our non-GLP preclinical oncology CRO services support early-stage drug discovery with integrated pharmacology, PK/PD modeling, and biomarker-driven strategies to accelerate lead optimization and candidate selection. We have deep expertise in immuno-oncology, including evaluation of checkpoint inhibitors, combination therapies, and immune-modulating agents using advanced syngeneic, humanized, and xenograft tumor models.
Our capabilities span a range of clinically relevant cancer types, including breast, lung, colorectal, and bladder malignancies, enabling translational oncology studies that generate actionable efficacy, pharmacokinetic, and pharmacodynamic data.
Powered Research partners with biotech and pharmaceutical companies seeking flexible, high-quality non-GLP oncology studies to de-risk pipelines and support IND-enabling research.
For a detailed listing of our preclinical oncology capabilities, view our brochure:
Explore our FAQs for more information
Contact Powered Research to design your next preclinical oncology study.